Long-Term Outcome of Treatment with 2% Topical Ganciclovir Solution in Cytomegalovirus Anterior Uveitis and Corneal Endotheliitis

References

• Chee S-P, Bacsal K, Jap A, Se-Thoe S-Y, Cheng CL, Tan BH. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008;145(5):834–840.e831. doi:10.1016/j.ajo.2007.12.015
   PubMed Web of Science ®Google Scholar
• Koizumi N, Suzuki T, Uno T, et al. Cytomegalovirus as an etiologic factor in corneal endotheliitis. Ophthalmology. 2008;115(2):292–297.e293. doi:10.1016/j.ophtha.2007.04.053
   PubMed Web of Science ®Google Scholar
• van Boxtel LAA, van der Lelij A, van der Meer J, Los LI. Cytomegalovirus as a cause of anterior uveitis in immunocompetent patients. Ophthalmology. 2007;114(7):1358–1362. doi:10.1016/j.ophtha.2006.09.035
   PubMed Web of Science ®Google Scholar
• Woo JH, Lim WK, Ho SL, Teoh SC. Characteristics of cytomegalovirus uveitis in immunocompetent patients. Ocul Immunol Inflamm. 2015;23(5):378–383. doi:10.3109/09273948.2014.950384
   PubMed Web of Science ®Google Scholar
• Carmichael A. Cytomegalovirus and the eye. Eye. 2012;26(2):237–240. doi:10.1038/eye.2011.327
   PubMed Web of Science ®Google Scholar
• Park SW, Yu HG. Association of cytomegalovirus with idiopathic chronic anterior uveitis with ocular hypertension in Korean patients. Ocul Immunol Inflamm. 2013;21(3):192–196. doi:10.3109/09273948.2012.754908
   PubMed Web of Science ®Google Scholar
• Chee S-P, Bacsal K, Jap A, Se-Thoe S-Y, Cheng CL, Tan BH. Corneal endotheliitis associated with evidence of cytomegalovirus infection. Ophthalmology. 2007;114(4):798–803. doi:10.1016/j.ophtha.2006.07.057
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Dussaix E, Cerqueti P, Patarin D. Possible role of cytomegalovirus infection in the etiology of the Posner-Schlossman syndrome. Int Ophthalmol. 1987;11(2):95–96. doi:10.1007/BF00136737
   PubMed Web of Science ®Google Scholar
• Sheng Q, Zhai R, Fan X, Kong X. The analysis of dynamic changes and prognosis of Posner-Schlossman syndrome with cytomegalovirus infection and antiviral therapy. J Ophthalmol. 2021;2021:6687929. doi:10.1155/2021/6687929
   PubMed Web of Science ®Google Scholar
• Su CC, Wang IJ, Chen WL, Lin CP, His B, Hu FR. Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty. Clin Exp Ophthalmol. 2013;41(4):339–347. doi:10.1111/j.1442-9071.2012.02888.x
   Web of Science ®Google Scholar
• Wong JXH, Agrawal R, Wong EPY, Teoh SC. Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis. J Ophthalmic Inflamm Infect. 2016;6(1):10. doi:10.1186/s12348-016-0078-z
   PubMedGoogle Scholar
• Koizumi N, Miyazaki D, Inoue T, et al. The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis. Br J Ophthalmol. 2017;101(2):114. doi:10.1136/bjophthalmol-2015-308238
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol. 2010;94(12):1648–1652. doi:10.1136/bjo.2009.167767
   PubMed Web of Science ®Google Scholar
• Pavan-Langston D, Welch CL, Zegans ME. Ganciclovir gel for cytomegalovirus keratouveitis. Ophthalmology. 2012;119(11):2411. doi:10.1016/j.ophtha.2012.07.024
   PubMed Web of Science ®Google Scholar
• Sheng Q, Zhai R, Fan X, Kong X. 2% ganciclovir eye drops control Posner-Schlossman syndrome relapses with/without cytomegalovirus intraocular reactivation. Front Med. 2022;9:848820. doi:10.3389/fmed.2022.848820
   Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature working G. standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Su -C-C, Hu F-R, Wang T-H, et al. Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy. Am J Ophthalmol. 2014;158(5):1024–1031.e1022. doi:10.1016/j.ajo.2014.08.007
   PubMed Web of Science ®Google Scholar
• Mietz H, Aisenbrey S, Ulrich bartz-schmidt K, Bamborschke S, Krieglstein GK. Ganciclovir for the treatment of anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2000;238(11):905–909. doi:10.1007/s004170000193
   PubMed Web of Science ®Google Scholar
• Accorinti M, Gilardi M, Pirraglia MP, et al. Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. Graefes Arch Clin Exp Ophthalmol. 2014;252(11):1817–1824. doi:10.1007/s00417-014-2782-4
   PubMed Web of Science ®Google Scholar
• Waduthantri S, Zhou L, Chee S-P. Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: a pilot study. PLoS One. 2018;13(1):e0191850–e0191850. doi:10.1371/journal.pone.0191850
   PubMed Web of Science ®Google Scholar
• Keorochana N, Choontanom R. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis. BMJ Open Ophthalmol. 2017;2(1):e000061. doi:10.1136/bmjophth-2016-000061
   PubMed Web of Science ®Google Scholar
• Fan NW, Chung YC, Liu YC, Liu CJ, Kuo YS, Lin PY. Long-term topical ganciclovir and corticosteroids preserve corneal endothelial function in cytomegalovirus corneal endotheliitis. Cornea. 2016;35(5):596–601. doi:10.1097/ICO.0000000000000791
   PubMed Web of Science ®Google Scholar
• Upadhyayula S, Michaels MG, Ganciclovir F. Cidofovir: antiviral drugs not just for cytomegalovirus. J Pediatric Infect Dis Soc. 2013;2(3):286–290. doi:10.1093/jpids/pit048
   Google Scholar
• Sira M, Murray PI. Treatment of cytomegalovirus anterior uveitis with oral valaciclovir. Ocul Immunol Inflamm. 2007;15(1):31–32. doi:10.1080/09273940601174038
   PubMed Web of Science ®Google Scholar
• de Schryver I, Rozenberg F, Cassoux N, et al. Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis. Br J Ophthalmol. 2006;90(7):852. doi:10.1136/bjo.2005.086546
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Canakis C, Zafirakis P, Marakis T, Mallias I, Theodossiadis G. Cytomegalovirus as a cause of anterior uveitis with sectoral iris atrophy. Ophthalmology. 2002;109(5):879–882. doi:10.1016/S0161-6420(02)00961-2
   PubMed Web of Science ®Google Scholar
• Sobolewska B, Deuter C, Doycheva D, Zierhut M. Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):117–124. doi:10.1007/s00417-013-2535-9
   PubMed Web of Science ®Google Scholar
• Chung RSH, Chua CN. Intravitreal ganciclovir injections in aqueous cytomegalovirus DNA positive hypertensive iritis. Eye. 2006;20(9):1080. doi:10.1038/sj.eye.6702112
   PubMed Web of Science ®Google Scholar
• Harada Y, Fukuda K, Nakahira A, Tada K, Sumi T, Fukushima A. Requirement of longer term antiviral therapy in patients with cytomegalovirus anterior uveitis with corneal endothelial cell damage. Clin Ophthalmol. 2018;12:1311. doi:10.2147/OPTH.S164184
   Web of Science ®Google Scholar
• Kandori M, Miyazaki D, Yakura K, et al. Relationship between the number of cytomegalovirus in anterior chamber and severity of anterior segment inflammation. Jpn J Ophthalmol. 2013;57(6):497–502. doi:10.1007/s10384-013-0268-2
   PubMed Web of Science ®Google Scholar